Neil Stahl, EVP Research and Development at REGENERON PHARMACEUTICALS, INC. (REGN), sold 35,215 shares at $444.65 ($15.9M) on 2020-02-27, disclosed to the SEC on 2020-02-28.
Open-market sale of $15.9M REGN by EVP Research and Development. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $451.89 | 14,651 | $6.6M | 41.6% |
| 2 | $435.93 | 209 | $91K | 0.6% |
| 3 | $435.93 | 209 | $91K | 0.6% |
| 4 | $436.43 | 348 | $152K | 1.0% |
| 5 | $436.43 | 348 | $152K | 1.0% |
| 6 | $437.41 | 480 |
| $210K |
| 1.3% |
| 7 | $437.41 | 480 | $210K | 1.3% |
| 8 | $438.63 | 256 | $112K | 0.7% |
| 9 | $438.63 | 256 | $112K | 0.7% |
| 10 | $439.73 | 231 | $102K | 0.6% |
| 11 | $439.73 | 231 | $102K | 0.6% |
| 12 | $440.24 | 395 | $174K | 1.1% |
| 13 | $440.24 | 395 | $174K | 1.1% |
| 14 | $443.67 | 264 | $117K | 0.7% |
| 15 | $443.67 | 264 | $117K | 0.7% |
| 16 | $444.65 | 490 | $218K | 1.4% |
| 17 | $444.65 | 490 | $218K | 1.4% |
| 18 | $445.91 | 120 | $54K | 0.3% |
| 19 | $445.91 | 120 | $54K | 0.3% |
| 20 | $448.86 | 240 | $108K | 0.7% |
| 21 | $448.86 | 240 | $108K | 0.7% |
| 22 | $449.53 | 236 | $106K | 0.7% |
| 23 | $449.53 | 236 | $106K | 0.7% |
| 24 | $450.10 | 125 | $56K | 0.4% |
| 25 | $450.10 | 125 | $56K | 0.4% |
| 26 | $451.47 | 233 | $105K | 0.7% |
| 27 | $451.47 | 233 | $105K | 0.7% |
| 28 | $452.08 | 130 | $59K | 0.4% |
| 29 | $452.08 | 130 | $59K | 0.4% |
| 30 | $453.45 | 113 | $51K | 0.3% |
| 31 | $453.45 | 113 | $51K | 0.3% |
| 32 | $454.58 | 102 | $46K | 0.3% |
| 33 | $455.56 | 2,967 | $1.4M | 8.5% |
| 34 | $455.56 | 2,967 | $1.4M | 8.5% |
| 35 | $456.63 | 743 | $339K | 2.1% |
| 36 | $456.63 | 743 | $339K | 2.1% |
| 37 | $457.27 | 141 | $64K | 0.4% |
| 38 | $457.27 | 141 | $64K | 0.4% |
| 39 | $458.59 | 460 | $211K | 1.3% |
| 40 | $458.59 | 460 | $211K | 1.3% |
| 41 | $459.47 | 692 | $318K | 2.0% |
| 42 | $459.47 | 692 | $318K | 2.0% |
| 43 | $460.34 | 252 | $116K | 0.7% |
| 44 | $460.34 | 252 | $116K | 0.7% |
| 45 | $461.24 | 614 | $283K | 1.8% |
| 46 | $461.24 | 614 | $283K | 1.8% |
| 47 | $462.15 | 1 | $462 | 0.0% |
| 48 | $463.10 | 123 | $57K | 0.4% |
| 49 | $463.10 | 123 | $57K | 0.4% |
| 50 | $464.14 | 126 | $58K | 0.4% |
| 51 | $464.14 | 126 | $58K | 0.4% |
| 52 | $465.42 | 227 | $106K | 0.7% |
| 53 | $465.42 | 227 | $106K | 0.7% |
| 54 | $468.56 | 31 | $15K | 0.1% |
| Total | $452.09 avg | 35,215 | $15.9M | 100% |
| Filing → |
| REGN | SELL | 2023-08-23 | $19.6M | — | Filing → |
| REGN | SELL | 2022-08-08 | $28.4M | — | Filing → |
| REGN | SELL | 2021-05-18 | $18.2M | — | Filing → |